P-282JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

ABSTRACT:

SUBMITTER: Eric V 

PROVIDER: S-EPMC4984069 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature